Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program
31 July 2024 - 8:00PM
Business Wire
- Biocytogen granted IDEAYA an option for an exclusive worldwide
license for potential first-in-class B7H3/PTK7 topo-I-payload
bispecific antibody drug conjugate (BsADC) program
- B7H3/PTK7 co-expression found in multiple solid tumor types,
including double-digit percent prevalence in lung, colorectal, and
head and neck cancers
- Rational combo opportunities with IDEAYA’s DNA Damage Repair
(DDR) pipeline, including IDE161 (PARG)
- Targeting development candidate nomination in H2 2024
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen,
HKEX: 02315), a global biotech company focusing on the discovery of
novel antibody/ADC therapeutics, announced that it has entered into
an option and license agreement for a potential first-in-class
B7H3/PTK7 BsADC program with IDEAYA Biosciences, Inc. (Nasdaq:
IDYA), a precision medicine oncology company committed to the
discovery and development of targeted therapeutics.
“We are thrilled to announce our collaboration with IDEAYA to
explore the promising combination of our potential first-in-class
ADC and IDEAYA’s DDR small molecules,” said Dr. Yuelei Shen,
President and CEO of Biocytogen. “This partnership leverages our
cutting-edge RenLite® platform and proprietary linker-payload
technology to enhance the precision and potency of ADCs. IDEAYA's
strong determination and rich experience in drug development make
us confident that this therapy could be rapidly advanced to benefit
patients.”
“The potential first-in-class B7H3/PTK7 topo-I-payload BsADC
program has the potential to be developed as a monotherapy agent in
multiple solid tumor types, and advances IDEAYA’s broader corporate
strategy to enable wholly-owned first-in-class rational
combinations at the intersection of ADCs and small molecule
DDR-based therapies to deliver greater benefit for patients,” said
Yujiro S. Hata, President and Chief Executive Officer, IDEAYA
Biosciences.
The agreement grants IDEAYA an option for an exclusive worldwide
license from Biocytogen for a potential first-in-class B7H3/PTK7
topo-I-payload BsADC program. B7H3/PTK7 has been found to be
co-expressed in multiple solid tumor types, including double-digit
percent prevalence in lung, colorectal, and head and neck cancers,
among others.
Under the terms of the agreement, Biocytogen will receive an
upfront fee and upon an option exercise by IDEAYA, be entitled to
receive an option exercise fee, development and regulatory
milestones and commercial milestone payments, as well as
single-digit royalties on net sales. Total potential upfront,
option exercise and milestone payments equal an aggregate of $406.5
million, including development and regulatory milestones of $100.0
million.
Based on preclinical data, the potential first-in-class
B7H3/PTK7 topoisomerase-I-inhibitor-payload BsADC program has the
potential to be developed as a monotherapy agent and used in
combination with multiple programs in IDEAYA’s pipeline targeting
DDR-based therapies, including PARG inhibitor IDE161. A development
candidate nomination for the B7H3/PTK7 topoisomerase-I-inhibitor
payload BsADC program is targeted for the second half of 2024.
About Biocytogen Biocytogen (HKEX: 02315) is a global
biotechnology company that drives the research and development of
novel antibody-based drugs with innovative technologies. Founded on
gene editing technology, Biocytogen leverages genetically
engineered proprietary RenMice® (RenMabTM/ RenLite®/ RenNano®/
RenTCR-mimicTM ) platforms for fully human
monoclonal/bispecific/multispecific antibody discovery, bispecific
antibody-drug conjugate discovery, nanobody discovery and TCR-mimic
antibody discovery, and has established a sub-brand,
RenBiologicsTM, to explore global partnerships for an off-the-shelf
library of >400,000 fully human antibody sequences against
approximately 1000 targets for worldwide collaboration. As of
December 31, 2023, 103 therapeutic antibody and multiple clinical
asset co-development/out-licensing/transfer agreements and 47
target-nominated RenMice® licensing projects have been established
around the globe, including several partnerships with multinational
pharmaceutical companies (MNCs). Biocytogen pioneered the
generation of drug target knock-in humanized models for preclinical
research, and currently provides a few thousand off-the-shelf
animal and cell models under the company’s sub-brand, BioMiceTM,
along with preclinical pharmacology and gene-editing services for
clients worldwide. Headquartered in Beijing, Biocytogen has
branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San
Francisco), and Germany (Heidelberg). For more information, please
visit http://en.biocytogen.com.cn.
About IDEAYA Biosciences IDEAYA is a precision medicine
oncology company committed to the discovery and development of
targeted therapeutics for patient populations selected using
molecular diagnostics. IDEAYA’s approach integrates capabilities in
identifying and validating translational biomarkers with drug
discovery to select patient populations most likely to benefit from
its targeted therapies. IDEAYA is applying its research and drug
discovery capabilities to synthetic lethality – which represents an
emerging class of precision medicine targets.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240731592628/en/
Biocytogen Contacts Antibody assets and platforms:
BD-Licensing@biocytogen.com Media: pr@bbctg.com.cn
Investor and Media Contact IDEAYA Biosciences Andres Ruiz
Briseno SVP, Head of Finance and Investor Relations
investor@ideayabio.com
IDEAYA Biosciences (NASDAQ:IDYA)
Historical Stock Chart
From Jul 2024 to Aug 2024
IDEAYA Biosciences (NASDAQ:IDYA)
Historical Stock Chart
From Aug 2023 to Aug 2024